NeuroScientific Biopharmaceuticals Ltd. announced positive results of lead drug candidate EmtinBTM in a gold standard animal model of Multiple sclerosis (MS). The study was undertaken by leading contract research partner Biospective, Canada. Study Design The study was conducted in the myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (MOG-EAE) mouse model, the gold-standard animal model for replicating the inflammatory mechanisms of human MS. The study evaluated EmtinBTM across three dose groups, including 10mg/kg (Group B) & 20mg/kg (Group C) dosed daily, and an exploratory group of 40mg/kg dosed once every 3 days (Group D) with the drug administered for a period of 21-days following the onset of initial clinical symptoms in the mice.

Treatment effect was determined through comparison to the control group (Group A) which were animals that were disease induced (MOG-EAE), but were administered vehicle only (placebo) on a daily basis for the 21 day treatment period duration, acting as a negative control. The study was appropriately powered to provide confidence in results with N=16 animals in each group for Groups A-C, with the exploratory Group D inclusive of N=10 animals only. Key Clinical Assessments performed (a) The daily assessment of clinical symptoms for the duration of the study (21 days) was performed using a standardised scoring system.

Higher scores mean more severe symptoms. Day- on-day EAE Clinical Score and Cumulative EAE Clinical Scores were analysed. With the induction of the model there is an aggressive and progressive deterioration in the EAE Clinical Score.